Serum erythroferrone levels during the first month of life in premature infants

J Perinatol. 2022 Jan;42(1):97-102. doi: 10.1038/s41372-021-01184-6. Epub 2021 Aug 10.

Abstract

Objective: To examine erythroferrone (ERFE)-hepcidin iron regulation in premature infants under intensive care at risk of iron metabolic disorders.

Study design: A retrospective cohort recruited 31 infants with a birth weight of <1500 g hospitalized in a tertiary center. Their hematological status was measured at birth and 2 and 4 weeks of life.

Results: ERFE was positively correlated with the reticulocyte hemoglobin content at 2 (r2 = 0.2374) and 4 weeks (r2 = 0.6005). An assumed negative correlation between ERFE and hepcidin was not determined during the neonatal period. Hepcidin was positively correlated with the leukocyte count (r2 = 0.3089) and ferritin (r2 = 0.7476) at birth and C-reactive protein (r2 = 0.3591) at 2 weeks and negatively correlated with the reticulocyte count (r2 = 0.2887) at 4 weeks.

Conclusion: The vulnerability of the ERFE-hepcidin pathway within 4 weeks may contribute to iron imbalance in premature infants.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hepcidins / metabolism
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Infant, Premature, Diseases*
  • Iron
  • Peptide Hormones* / metabolism
  • Retrospective Studies

Substances

  • Erfe protein, human
  • Hepcidins
  • Peptide Hormones
  • Iron